EuBiologics Overview
- Year Founded
-
2010
- Status
-
Public
- Employees
-
335
- Stock Symbol
-
206650
- Investments
-
4
- Share Price
-
$7.92
- (As of Monday Closing)
EuBiologics General Information
Description
EuBiologics Co Ltd is a biopharmaceutical company, which develops and supplies vaccines for epidemics and antibiotic resistance in South Korea. It offers Euvchol, an oral cholera prevention vaccine; and CRM197, a diphtheria toxin mutant vaccine, Inaba Cairo, and among others.
Contact Information
Website
www.eubiologics.comCorporate Office
- 8F, Seongdo Building, 207, Dosan-daero
- Sinsa-dong, Gangnam-gu
- Seoul
- South Korea
Corporate Office
- 8F, Seongdo Building, 207, Dosan-daero
- Sinsa-dong, Gangnam-gu
- Seoul
- South Korea
EuBiologics Stock Performance
As of 10-Feb-2025, EuBiologics’s stock price is $7.92. Its current market cap is $290M with 36.5M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $7.92 | $7.83 | $6.88 - $13.61 | $290M | 36.5M | 299K | -$0.29 |
EuBiologics Financials Summary
As of 31-Dec-2023, EuBiologics has a trailing 12-month revenue of $53.1M.
|
In Thousands, USD |
TTM 31-Dec-2023 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 324,466 | 324,466 | 254,549 | 1,052,525 |
| Revenue | 53,054 | 53,054 | 42,927 | 34,385 |
| EBITDA | (3,485) | (3,485) | 3,731 | (20,756) |
| Net Income | (10,615) | (10,615) | (850) | (24,073) |
| Total Assets | 117,799 | 117,799 | 128,327 | 126,416 |
| Total Debt | 11,468 | 11,468 | 12,402 | 13,043 |
EuBiologics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
EuBiologics Patents
EuBiologics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240148856-A1 | Respiratory syncytial virus vaccine | Pending | 03-Nov-2022 | ||
| EP-4212173-A1 | Vaccine composition for chickenpox or varicella zoster and method of using same | Pending | 11-Sep-2020 | ||
| US-20240033346-A1 | Vaccine composition for chickenpox or varicella zoster and method of using same | Pending | 11-Sep-2020 | ||
| EP-4212173-A4 | Vaccine composition for chickenpox or varicella zoster and method of using same | Pending | 11-Sep-2020 | ||
| EP-4026842-A1 | Crm197 protein expression method | Pending | 03-Sep-2019 | C07K14/34 |
EuBiologics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
EuBiologics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
EuBiologics Investments (4)
EuBiologics’s most recent deal was a Early Stage VC with LISCure Biosciences for . The deal was made on 25-Feb-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| LISCure Biosciences | 25-Feb-2021 | Early Stage VC | Drug Discovery | ||
| POP Biotechnologies | 16-Jul-2020 | Corporate | Drug Discovery | ||
| Premium Vaccine Devloper (Eubiologic /POP Biotech) | 12-Jun-2020 | Joint Venture | Biotechnology | ||
| ATGC (Biotechnology) | 01-Jan-2019 | Later Stage VC | Biotechnology |
EuBiologics ESG
Risk Overview
Risk Rating
Updated December, 24, 2022
44.04 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,120
Rank
Percentile
Pharmaceuticals
Industry
of 853
Rank
Percentile
Pharmaceuticals
Subindustry
of 425
Rank
Percentile
EuBiologics FAQs
-
When was EuBiologics founded?
EuBiologics was founded in 2010.
-
Where is EuBiologics headquartered?
EuBiologics is headquartered in Seoul, South Korea.
-
What is the size of EuBiologics?
EuBiologics has 335 total employees.
-
What industry is EuBiologics in?
EuBiologics’s primary industry is Drug Discovery.
-
Is EuBiologics a private or public company?
EuBiologics is a Public company.
-
What is EuBiologics’s stock symbol?
The ticker symbol for EuBiologics is 206650.
-
What is the current stock price of EuBiologics?
As of 10-Feb-2025 the stock price of EuBiologics is $7.92.
-
What is the current market cap of EuBiologics?
The current market capitalization of EuBiologics is $290M.
-
What is EuBiologics’s current revenue?
The trailing twelve month revenue for EuBiologics is $53.1M.
-
What is EuBiologics’s annual earnings per share (EPS)?
EuBiologics’s EPS for 12 months was -$0.29.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
